Dataset Information


Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.

ABSTRACT: The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2?mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.A microtracer study approach, in which a 5??g radiolabelled i.v. microdose of trametinib was given concomitantly with an unlabelled 2?mg oral tablet formulation, was used to recover i.v. and oral pharmacokinetic parameters, simultaneously.The least-squares mean (90% confidence interval) absolute bioavailability of trametinib (2?mg tablet) was 72.3% (50.0%, 104.6%). Median tmax after oral administration was 1.5?h and the geometric mean terminal half-life was 11?days. The geometric mean clearance and volume of distribution after i.v. administration were 3.21?l?h(-1) and 976?l, respectively, resulting in a terminal elimination half-life of 11?days.Trametinib absolute bioavailability was moderate to high, whereas first pass metabolism was low.

SUBMITTER: Leonowens C 

PROVIDER: S-EPMC4243903 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5099557 | BioStudies
2020-01-01 | S-EPMC7360017 | BioStudies
2019-01-01 | S-EPMC6850403 | BioStudies
2018-01-01 | S-EPMC6039199 | BioStudies
2018-01-01 | S-EPMC6028879 | BioStudies
2018-01-01 | S-EPMC5947295 | BioStudies
1000-01-01 | S-EPMC5593165 | BioStudies
2018-01-01 | S-EPMC6282586 | BioStudies
2020-01-01 | S-EPMC7497692 | BioStudies
2016-01-01 | S-EPMC4833163 | BioStudies